Originally developed for type 2 diabetes and obesity management, GLP‐1 RAs act through multiple mechanisms including appetite suppression, delayed gastric emptying, and enhanced insulin sensitivity.1, 3. The gene discussed is GLP1R; the disease is obesity disorder.